Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...

The VanEck Biotech ETF (BBH) was launched on December 20, 2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity ...

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

Virtus LifeSci Biotech Clinical Trials ETF BBC is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 138.3% from its 52-week low price of $13.42/share.

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

iShares Biotechnology ETF (NASDAQ:IBB) - $0.0828. Payable Sep 19; for shareholders of record Sep 16; ex-div Sep 16. BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH Biotech Looks ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

Bank Julius Baer & Co. Ltd Zurich lowered its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 95.7% in the 1st quarter, according to its most recent disclosure with the Securities ...